|Targets||Polo-like Kinase (PLK)|
|Description||TAK-960 is an orally available, potent and selective PLK1 inhibitor that was in a phase I clinical trial in patients with advanced non-hematologic malignancies.|
|Synonyms||4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide;dihydrochloride; TAK-960 (dihydrochloride); TAK 960 (dihydrochloride); TAK960 (dihydrochloride)|
|Solubility||DMSO: ≥ 98.57 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. SBE13 does not effect the activi...
MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lin...
SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. Its IC50 value is 0.2 nM. It doe...
Centrinone, a pyrimidinamine derivative, has been found to be a high affinity and selective PLK4 inhibitor (Ki = 0.16 nM).
HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kin...
Poloxin is the first small-molecule inhibitor specifically targeting the function of the Plk1 PBD. Poloxin induces centrosome fragmentation and abnormal spindle...
Rigosertib (ON-01910 sodium salt), a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity, is a non-ATP-competitive inhibitor of PLK1...
NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-l...